Form 4: ALX Oncology Director Acquires Stock Options

Director Rekha Hemrajani acquired 20,200 stock options in ALX Oncology Holdings Inc. on June 13, 2024.

Summary

• On June 13, 2024, Rekha Hemrajani, a director of ALX Oncology Holdings Inc., acquired 20,200 stock options.
• The exercise price of these options is $8.44.
• The options vest in 12 equal monthly installments starting on the 13th day of each month, or the day before the next annual meeting of stockholders, and expire on June 12, 2034.
• Following the transaction, Hemrajani directly owns 20,200 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director could be seen as a positive signal, indicating confidence in the company's future performance.

Industry Context

This is a standard Form 4 filing, reflecting a change in beneficial ownership by a company insider. Option grants are a common form of executive compensation in the biotechnology industry.

Comparison to Industry Standards

• Stock option grants are a typical component of compensation packages for directors in publicly traded biotechnology companies.
• The vesting schedule of 12 months is also a common practice to incentivize long-term commitment.
• Comparable companies such as Amgen, Gilead, and Biogen also utilize stock options as part of their executive compensation plans.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of director confidence.

Key Dates